Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Moffitt Cancer Center

Sites in Tampa, FL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 7:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
710
Shown on this page
12
Current sort
Recently updated
Campus scope
Moffitt Cancer Center, Tampa, FL
Additional filters apply within this campus.

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

Filter and sort this campus

These controls apply only within Moffitt Cancer Center, Tampa, FL. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 277–288 of 710 matching trials with a site at Moffitt Cancer Center, Tampa, FL.
Indexed local directory records.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Stored official records

Active, not recruiting Phase 2 Interventional Results available

Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer

NCT03367741
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Nivolumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 15, 2026, 9:22 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT02890329
Site status not listed — check the official record
View directory record Official record
Conditions
Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Myelodysplasia-Related, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
Interventions
Decitabine, Ipilimumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
11
States / cities
Duarte, California • La Jolla, California • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 13, 2026, 4:57 PM EDT
Recruiting Phase 1 Interventional

Study of FID-022 in Participants With Advanced Solid Tumors

NCT06694480
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
FID-022
Drug
Lead sponsor
Fulgent Pharma LLC.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 16, 2026, 7:35 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

NCT04340843
Site status not listed — check the official record
View directory record Official record
Conditions
Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma
Interventions
Belinostat, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Decitabine and Cedazuridine, Guadecitabine, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
39
States / cities
Phoenix, Arizona • Duarte, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 15, 2026, 8:20 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma

NCT04339738
Site status not listed — check the official record
View directory record Official record
Conditions
Skin Angiosarcoma, Skin Radiation-Related Angiosarcoma, Visceral Angiosarcoma
Interventions
Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, Nivolumab, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
170
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 120 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 15, 2026, 8:07 PM EDT
Recruiting Phase 1 Interventional

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

NCT03666000
Status at this site: Recruiting
View directory record Official record
Conditions
B-cell Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, Small Lymphocytic Lymphoma
Interventions
Azer-cel, Cyclophosphamide, Fludarabine, IL-2, Ibrutinib, Acalabrutinib, Zanubrutinib, or Pirtobrutinib
Biological · Drug
Lead sponsor
Imugene Limited
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
10
States / cities
Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 10, 2026, 8:15 PM EDT
Recruiting No phase listed Observational

Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy

NCT07144319
Status at this site: Recruiting
View directory record Official record
Conditions
Bladder Cancer, Non-muscle Invasive Bladder Cancer
Interventions
Not listed
Lead sponsor
Photocure
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Tampa, Florida • Ann Arbor, Michigan • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 16, 2026, 6:43 AM EDT
Recruiting Phase 1Phase 2 Interventional

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

NCT07012031
Status at this site: Recruiting
View directory record Official record
Conditions
Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Sotorasib, Trastuzumab Deruxtecan
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Sacramento, California • Tampa, Florida • Wesley Chapel, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 16, 2026, 5:12 AM EDT
Recruiting Phase 1 Interventional

Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors

NCT06014502
Status at this site: Recruiting
View directory record Official record
Conditions
Solid Tumor
Interventions
IMGS-001
Drug
Lead sponsor
ImmunoGenesis
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
13
States / cities
Gilbert, Arizona • Orange, California • Santa Monica, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Sep 17, 2026, 4:29 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

NCT05315700
Status at this site: Recruiting
View directory record Official record
Conditions
Solid Tumors
Interventions
Chemotherapy drug, ORIC-114
Drug
Lead sponsor
ORIC Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Duarte, California • Huntington Beach, California • Irvine, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 1, 2026, 8:10 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

First-in-Human Study of ICT01 in Patients With Advanced Cancer

NCT04243499
Site status not listed — check the official record
View directory record Official record
Conditions
Hematopoietic/Lymphoid Cancer, Solid Tumor, Adult
Interventions
IV ICT01
Biological
Lead sponsor
ImCheck Therapeutics, an Ipsen company
Industry
Eligibility
18 Years and older
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
Gilbert, Arizona • Duarte, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 16, 2026, 2:11 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

NCT03386513
Site status not listed — check the official record
View directory record Official record
Conditions
Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm
Interventions
IMGN632
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
16
States / cities
Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 16, 2026, 12:19 AM EDT

About this Moffitt Cancer Center institution page

What this page lists
ClinicalTrials.gov records that list Moffitt Cancer Center in Tampa, FL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.